Receptors, Vascular Endothelial Growth Factor
"Receptors, Vascular Endothelial Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular Ig-like domains which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.
MeSH Number(s)
D08.811.913.696.620.682.725.400.950
D12.776.543.750.060.750
D12.776.543.750.750.400.910
Concept/Terms
Receptors, Vascular Endothelial Growth Factor- Receptors, Vascular Endothelial Growth Factor
- Receptor, Vascular Permeability Factor
- Vascular Endothelial Cell Growth Factor Receptor
- Vascular Endothelial Growth Factor Receptor
- VEGF Receptor
- VEGF Receptors
- Receptors, VEGF
- VPF Receptor
- Receptor, Vascular Endothelial Cell Growth Factor
- Vascular Permeability Factor Receptor
Below are MeSH descriptors whose meaning is more general than "Receptors, Vascular Endothelial Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Vascular Endothelial Growth Factor".
This graph shows the total number of publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Vascular Endothelial Growth Factor" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 3 | 3 |
| 1994 | 0 | 3 | 3 |
| 1995 | 0 | 8 | 8 |
| 1996 | 0 | 9 | 9 |
| 1997 | 0 | 8 | 8 |
| 1998 | 0 | 9 | 9 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 15 | 15 |
| 2001 | 0 | 21 | 21 |
| 2002 | 0 | 18 | 18 |
| 2003 | 1 | 2 | 3 |
| 2004 | 1 | 3 | 4 |
| 2005 | 5 | 6 | 11 |
| 2006 | 3 | 4 | 7 |
| 2007 | 5 | 9 | 14 |
| 2008 | 4 | 9 | 13 |
| 2009 | 6 | 15 | 21 |
| 2010 | 7 | 12 | 19 |
| 2011 | 4 | 10 | 14 |
| 2012 | 9 | 13 | 22 |
| 2013 | 8 | 10 | 18 |
| 2014 | 17 | 11 | 28 |
| 2015 | 14 | 7 | 21 |
| 2016 | 11 | 12 | 23 |
| 2017 | 8 | 7 | 15 |
| 2018 | 7 | 10 | 17 |
| 2019 | 6 | 7 | 13 |
| 2020 | 3 | 3 | 6 |
Below are the most recent publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Profiles.
-
Treatment of Experimental Choroidal Neovascularization via RUNX1 Inhibition. Am J Pathol. 2021 03; 191(3):418-424.
-
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2020 12 15; 324(23):2383-2395.
-
Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol. 2020 06 01; 138(6):698-701.
-
Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020 05 05; 5:CD012208.
-
Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020 04 01; 138(4):341-349.
-
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology. 2020 09; 127(9):1201-1210.
-
RIP1 kinase mediates angiogenesis by modulating macrophages in experimental neovascularization. Proc Natl Acad Sci U S A. 2019 11 19; 116(47):23705-23713.
-
Epoxyeicosatrienoic acid (EET)-stimulated angiogenesis is mediated by epoxy hydroxyeicosatrienoic acids (EHETs) formed from COX-2. J Lipid Res. 2019 12; 60(12):1996-2005.
-
A Surgical Technique for the Management of Tractional Retinal Detachment in Aggressive Posterior Retinopathy of Prematurity Treated With Intravitreal Bevacizumab. Retina. 2019 Oct; 39 Suppl 1:S156-S159.
-
Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor ß for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial. Ophthalmology. 2020 02; 127(2):211-220.